4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
December 04 2023 - 7:00AM
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company),
a clinical-stage biotherapeutics company with three novel, highly
targeted next generation AAV vectors currently in the clinic, today
announced that the initial interim landmark data analysis (24
weeks) from the randomized Dose Expansion stage (N=50) of the Phase
2 PRISM clinical trial in high anti-VEGF (vascular endothelial
growth factor) treatment need (6-12 anti-VEGF injections in prior
12 months) wet AMD patients will be presented at the Angiogenesis,
Exudation, and Degeneration 2024 Conference being held virtually on
February 3, 2024.
The Company will also host a webcast to discuss the data in
detail and include a 4D-150 program update with details to be
announced at a future date.
2024 Angiogenesis, Exudation, and Degeneration
Presentation Details:
Title: |
First Interim Results (24 weeks) for the Randomized Phase 2 Dose
Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need
Patients with nAMD |
Date/Time: |
Saturday, February 3, 2024 at
4:20 p.m. ET |
Presenter: |
Arshad M. Khanani, M.D., M.A.,
FASRS, Director of Clinical Research at Sierra Eye Associates,
Clinical Associate Professor at University of Nevada, Reno School
of Medicine |
|
|
The presentation from the Angiogenesis, Exudation, and
Degeneration 2024 Conference will also be available on the 4D
Molecular Therapeutics website under Scientific Presentations:
https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications
About 4D-150 for Wet AMD
4D-150 comprises our customized and evolved intravitreal vector,
R100, and a transgene cassette that expresses both aflibercept and
a VEGF-C inhibitory RNAi. This dual-transgene payload inhibits four
angiogenic factors that drive wet AMD and DME: VEGF A, B, C and
PlGF. R100 was invented at 4DMT through our proprietary Therapeutic
Vector Evolution platform; we invented this platform utilizing
principles of directed evolution, a Nobel Prize-winning technology.
4D-150 is designed for single, low-dose intravitreal delivery for
transgene expression from the retina without significant
inflammation.
About Wet AMD
Wet AMD is a highly prevalent disease with estimated incidence
rate of 200,000 new patients per year in the United States. It is
estimated that the total prevalence of wet AMD in the major
markets, including the U.S., EU (major markets), and Japan, is
approximately 3.1 million individuals. Wet AMD is a type of macular
degeneration where abnormal blood vessels (choroidal
neovascularization or CNV) grow into the macula, the central area
of the retina. As a consequence, CNV causes swelling and edema of
the retina, bleeding and scarring, and causes visual distortion and
reduced acuity. The proliferation and leakage of abnormal blood
vessels is stimulated by VEGF. This process distorts and can
potentially destroy central vision and may progress to blindness
without treatment.
About 4DMT
4DMT is a clinical-stage biotherapeutics company with three
novel, highly targeted next generation AAV vectors currently in the
clinic targeting multiple large market diseases in ophthalmology
and pulmonology, plus other therapeutic areas. 4DMT seeks to unlock
the full potential of genetic medicines using its proprietary
invention platform, Therapeutic Vector Evolution, which combines
the power of the Nobel Prize-winning technology, directed
evolution, with approximately one billion synthetic AAV
capsid-derived sequences to invent customized and evolved vectors
for use in our product candidates. All of our vectors are
proprietary to 4DMT and were invented at 4DMT, including the
vectors utilized in our clinical-stage and preclinical pipeline
product candidates: R100, A101, and C102. The Company is initially
focused on five clinical-stage product candidates in three
therapeutic areas for both rare and large market diseases:
ophthalmology, pulmonology, and cardiology. The 4DMT customized and
evolved vectors were invented with the goal of being delivered at
relatively low doses through clinically routine, well-tolerated,
and minimally invasive routes of administration, transducing
diseased cells in target tissues efficiently, having reduced
immunogenicity and, where relevant, having resistance to
pre-existing antibodies. 4DMT is currently advancing five product
candidates in clinical development: 4D-150 for wet AMD and DME,
4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease
cardiomyopathy, 4D-125 for XLRP, and 4D-110 for choroideremia. The
4D preclinical product candidates in development are: 4D-175 for
geographic atrophy and 4D-725 for AATLD.
4D-150, 4D-710, 4D-310, 4D-125, and 4D-110 are our product
candidates in clinical development and have not yet been approved
for marketing by the US FDA or any other regulatory authority. No
representation is made as to the safety or effectiveness of 4D-150,
4D-710, 4D-310, 4D-125, or 4D-110 for the therapeutic uses for
which they are being studied.
4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector
Evolution™, and the 4DMT logo are trademarks of 4DMT.
Contacts:
Media:
Katherine SmithEvoke CanaleKatherine.Smith@evokegroup.com
Investors:
Julian PeiHead of Investor Relations and Corporate
CommunicationsInvestor.Relations@4DMT.com267-644-5097
4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
From Apr 2024 to May 2024
4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart
From May 2023 to May 2024